At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
vorinostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Evaluation of Suberoylanilide Hydroxamic Acid (NSC 701852) in Patients With Advanced Prostate Cancer That Has Progressed on One Prior Chemotherapy
In Brief
A Phase 2 clinical trial evaluating vorinostat and laboratory biomarker analysis for Recurrent Prostate Cancer and Stage IV Prostate Cancer. Completed, enrolled 29 participants across 1 site.
Detailed Summary
This phase II trial is studying how well vorinostat works in treating patients with progressive metastatic prostate cancer. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedMay 2006
Primary CompletionSep 2009
Study CompletionMay 2011
TodayJul 2026
First PostedMay 26, 2006
Enrollment StartMar 1, 2006
Primary CompletionSep 1, 2009
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 20.1 years ago
Interventions
vorinostatdrug
Given orally
laboratory biomarker analysisother
Correlative studies